https://doi.org/10.1016/j.envint.2022.107366

Michal Pardo^a, Svenja Offer^bc, Elena Hartner^bc, Sebastiano Di Bucchianico^b, Christoph Bisig^b, Stefanie Bauer^b, Jana Pantzke^bc, Elias J. Zimmermann^bc, XinCao^bc, Stephanie Binder^bc, Evelyn Kuhn^b, Anja Huber^b, Seongho Jeong^bc, Uwe Käfer^bc, Eric Schneider^c,[...]

^a Department of Earth and Planetary Sciences, Faculty of Chemistry, Weizmann Institute of Science, 234 Herzl Street, POB 26, ISR-7610001 Rehovot, Israel
^b Joint Mass Spectrometry Center (JMSC) at Comprehensive Molecular Analytics (CMA), Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany
^c Joint Mass Spectrometry Center (JMSC) at Analytical Chemistry, Institute of Chemistry, University of Rostock, Dr.-Lorenz-Weg 2, D-18059 Rostock, Germany
^d Department of Environmental and Biological Sciences, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, FI-70210 Kuopio, Finland
^e University of the Bundeswehr Munich, Institute for Chemistry and Environmental Engineering, Werner- Heisenberg-Weg 39, D-85577 Neubiberg, Germany
^f Institute for Environmental Studies, Faculty of Science, Charles University, Albertov 6, CZE-12800 Prague, Czech Republic
^g Department of Applied Physics, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, FI-70210 Kuopio, Finland
^h Institute of Energy and Climate Research, Troposphere (IEK-8), Forschungszentrum Jülich GmbH, Wilhelm-Johen-Str., D-52428 Jülich, Germany
ⁱ Department of Environmental Sciences, University of Basel, Klingelbergstr. 27, CH-4056 Basel, Switzerland
^j Max-Delbrück-Centrum für Molekulare Medizin (MDC), Robert-Rössle-Str. 10, D-13125 Berlin, Germany
^k Institute of Computational Biology, Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany
^l The Mantoux Bioinformatics Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot 76100, Israel

Read more

Aerosol exposure for breathing AX Lung-on-Chip

The VITROCELL® Cloud Alpha AX12 is our newest innovation in the Cloud family and presents a great leap forward in automated exposure of cell cultures with breathing function. It combines highly efficient testing with ease of use. The development is based on the well-known and frequently published VITROCELL® Cloud formats (6-, 12-, 24- and 96-well).
Its functionality enables fully automated processes with an all-in-one control unit. Everyday experiments at the Air/Liquid Interface have never been easier.

It is suitable for the nebulization of solutions and suspensions. Fields of application are, but are not limited to, screening of inhaled drugs and toxicity testing of inhaled substances such as chemicals, nanoparticles and airborne pathogens.

VITROCELL® Cloud Alpha AX 12  (PDF)

Read more

Increase of nebulizations and evacuation of residual gaseous compounds

A typical Cloud exposure allows 3 consecutive nebulizations. The PowerVent option enables an increase of the dose by adding further nebulizations. After each nebulization the humidity is removed by a short venting period before starting the new one. The venting function can be edited in the software. The PowerVent unit is delivered ready-to-use with an integrated vacuum pump.

VITROCELL® Cloud Alpha PowerVent  (PDF)

Read more

Now Heated Tobacco Products (HTP) can be continuously smoked with automatic button actuation. The heat-and-turn feature for heat-not-burn devices enables automatic smoking at all 10 ports of the VC 10 S-TYPE Robot. Selective guidance of the aerosol to max. 6 exhaust lines is possible as well.

VITROCELL Application Note

Watch the video on Youtube

Read more

https://doi.org/10.1016/j.bbrep.2021.101187

David Bovard ^b, Marco van der Toorn ^b, Walter K. Schlage ^a, Samuel Constant ^c, Kasper Renggli ^b, Manuel C. Peitsch ^b, Julia Hoeng ^b,
^a Biology Consultant, Max-Baermann-Str. 21, 51429, Bergisch Gladbach, Germany
^b PMI R&D, Philip Morris Products S.A, Quai Jeanrenaud 5, 2000, Neuchaˆtel, Switzerland
^c Epithelix Sarl, 18 Chemin des Aulx, Plan-les-Ouates, 1228, Geneva, Switzerland

This study successfully demonstrates the exposure of human bronchial epithelial cultures to defined doses of nebulized Iota-carrageenan which were reproducibly generated and administered using the VITROCELL Cloud 12 system. 
The aim of this study was to further investigate the efficacy and safety of IC treatment on SARS-CoV-2 infection by using advanced in vitro models of human respiratory epithelium, the primary target and entry port of SARS-CoV-2. The experimental models were 3D cultures of reconstituted bronchial and nasal epithelia, representing the surface of the human upper respiratory tract. This apical exposure of reconstructed epithelia more closely mimics real-life exposure conditions and the absence of toxicity or any functional or structural impairment of the bronchial mucociliary epithelium demonstrates that topical treatment with nebulized IC is well tolerated at the effective concentrations. 

Read more